ModernaMRNA
MRNA
About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Employees: 5,800
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
14% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 8 (+1) [Q4]
4.34% more ownership
Funds ownership: 67.5% [Q3] → 71.84% (+4.34%) [Q4]
9% less repeat investments, than reductions
Existing positions increased: 226 | Existing positions reduced: 248
6% less funds holding
Funds holding: 771 [Q3] → 722 (-49) [Q4]
16% less first-time investments, than exits
New positions opened: 138 | Existing positions closed: 165
20% less call options, than puts
Call options by funds: $929M | Put options by funds: $1.16B
34% less capital invested
Capital invested by funds: $17.3B [Q3] → $11.5B (-$5.82B) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$33
5%
upside
Avg. target
$45
44%
upside
High target
$78
148%
upside
9 analyst ratings
1 positive
11%
6 neutral
67%
2 negative
22%
JP Morgan Jessica Fye 67% 1-year accuracy 26 / 39 met price target | 5%upside $33 | Underweight Maintained | 21 Mar 2025 |
Citigroup Geoff Meacham 63% 1-year accuracy 19 / 30 met price target | 27%upside $40 | Neutral Initiated | 13 Mar 2025 |
UBS Eliana Merle 32% 1-year accuracy 6 / 19 met price target | 148%upside $78 | Buy Maintained | 19 Feb 2025 |
RBC Capital Luca Issi 36% 1-year accuracy 20 / 56 met price target | 27%upside $40 | Sector Perform Reiterated | 18 Feb 2025 |
Barclays Gena Wang 24% 1-year accuracy 7 / 29 met price target | 43%upside $45 | Equal-Weight Downgraded | 18 Feb 2025 |
Financial journalist opinion
Based on 34 articles about MRNA published over the past 30 days
Positive
The Motley Fool
6 days ago
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Valuation always matters in investing. And sometimes you can find stocks that are especially great bargains.
Positive
Zacks Investment Research
6 days ago
Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Positive
The Motley Fool
1 week ago
4 Things You Need to Know if You Buy Moderna Stock Today
It's been nearly five years since Moderna (MRNA -1.60%) emerged as a biotech industry disruptor, with its COVID-19 vaccine playing a landmark role in tackling the global pandemic in late 2020. Despite its generating record sales and profits through 2022, early projections of sustained demand for coronavirus vaccinations failed to materialize, leading to a sharp drop in the business.
Positive
The Motley Fool
1 week ago
2 No-Brainer Biotech Stocks to Buy Right Now
Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock might soar as investors bet on the company's cutting-edge technology through its development stages -- and the stock could continue to gain after that company moves into the product commercialization stage.
Negative
Zacks Investment Research
1 week ago
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
Given the uncertainty around its top-line growth, short-term investors should exercise caution when investing in MRNA stock.
Neutral
GlobeNewsWire
1 week ago
mRNA Vaccines Market Trends and Competition Analysis 2025-2030: Revenues are Projected to Nearly Double, Growing by ~$8 Billion
Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The mRNA Vaccines Market grew from USD 9.32 billion in 2024 to USD 10.40 billion in 2025. It is expected to continue growing at a CAGR of 11.86%, reaching USD 18.28 billion by 2030. The mRNA vaccine landscape has experienced transformative shifts that underscore the evolution of medical innovation and technological integration. In recent years, unprecedented advances in formulation techniques and delivery systems have redefined the boundaries of vaccine development. Enhanced methods in nucleoside modification, lipid nanoparticle encapsulation, and self-amplifying mRNA platforms mean that vaccines can be deployed more precisely and at greater speeds than previously imagined. These transformative shifts are not limited solely to the technology itself; the regulatory environment, industrial collaborations, and public-private partnerships have advanced in tandem with scientific breakthroughs. A reformed regulatory outlook coupled with robust funding models has helped streamline clinical trials and expedite the approval process. Emerging trends indicate a movement away from traditional vaccine platforms toward more dynamic and responsive mRNA solutions that cater to rapidly changing health scenarios. As a result, industry participants are better positioned to anticipate market needs and harness the potential of mRNA. The emphasis on scalability and adaptability is evident in the way manufacturers and innovators are rethinking production methodologies. By investing in innovative manufacturing processes and reimagining the vaccine life cycle, key players are not only responding to current challenges but are also preparing to meet future public health demands. This evolution is transforming market dynamics while setting a new standard for what is achievable with modern vaccine technology. Global Regional Insights and Market Opportunities The global reach of mRNA vaccine technology offers a range of regional insights that are especially pertinent in today's connected world. In the Americas, strong investment in biotechnology research and development, coupled with robust healthcare infrastructure, has created fertile ground for mRNA innovations. North American markets, in particular, have been quick to adopt the latest vaccine technologies, leading to rapid integration into public health strategies. Europe, Middle East & Africa showcase a mixed landscape where advanced healthcare systems in parts of Europe drive market maturity, while emerging markets in the Middle East and Africa offer significant potential through rapidly evolving regulatory frameworks and government incentives. These regions demonstrate a balanced blend of established research excellence and untapped market potential. Meanwhile, the Asia-Pacific region stands out with its diverse market dynamics. The confluence of high population density, increasing bio-tech investments, and proactive government policies has fostered a thriving environment for mRNA vaccine development. The interplay between tradition and modernity in healthcare delivery, combined with improvements in regional manufacturing capacities, positions the Asia-Pacific as a vital market for future growth. These regional insights illustrate the broad geographic impact of mRNA vaccine innovation and underscore the importance of a tailored approach to market strategies in each region. Competitive Landscape The report delves into recent significant developments in the mRNA Vaccines Market, highlighting leading vendors and their innovative profiles. These include:
Negative
Zacks Investment Research
1 week ago
Moderna (MRNA) Advances But Underperforms Market: Key Facts
In the latest trading session, Moderna (MRNA) closed at $34.71, marking a +0.26% move from the previous day.
Positive
The Motley Fool
1 week ago
Down 93%, Is It Finally Time to Buy Moderna?
As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then. A few years ago, Moderna (MRNA 0.93%) stock soared on the back of the highly successful vaccine it developed in record time.
Negative
Market Watch
2 weeks ago
These 20 stocks are likely to be losers no matter what the market does
Difficult-to-short stocks are often greatly overvalued.
Neutral
Seeking Alpha
2 weeks ago
Moderna (MRNA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)
Moderna (NASDAQ:MRNA ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 1:30 PM ET Company Participants Rose Loughlin - EVP of Research Lavina Talukdar - SVP, Head of IR Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone. My name is Gena Wang.
Charts implemented using Lightweight Charts™